<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01053988</url>
  </required_header>
  <id_info>
    <org_study_id>112206</org_study_id>
    <nct_id>NCT01053988</nct_id>
  </id_info>
  <brief_title>A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>A 24-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components Delivered Once Daily (AM) Via a Novel Dry Powder Inhaler Compared With Placebo in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Purpose of this study is to assess the efficacy and safety of two strengths of the
      FF/GW642444 Inhalation Powder in subjects with chronic obstructive pulmonary disease (COPD)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 5, 2009</start_date>
  <completion_date type="Actual">April 14, 2011</completion_date>
  <primary_completion_date type="Actual">February 1, 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Weighted Mean FEV1 Over 0-4 Hours Post-dose at Day 168</measure>
    <time_frame>Baseline (BL) to Day 168</time_frame>
    <description>Co-Primary Endpoint: Pulmonary function was measured by forced expiratory volume in one second (FEV1), defined as the maximal amount of air that can be forcefully exhaled from the lungs in one second. Serial FEV1 measurements were taken electronically by spirometry at BL, weeks 2, 8, 12, and 84 (Day 168). Weighted mean (WM) was calculated using the 0 - 4 h post-dose FEV1 measurements that included the pre-dose (Day 1: 30 minutes [min] and 5 min prior to dosing; other serial visits:23 and 24 h after previous morning dose) and post-dose (5, 15, and 30 min and 1, 2, and 4 h) assessments. BL FEV1 is the mean of the two assessments made 30 and 5 min pre-dose at Day 1. WM change from BL was the WM at the visit minus the BL value. Analysis was performed using a repeated measures model with covariates of treatment, smoking status at screening (stratum), BL- mean of the two assessments made 30 and 5 min pre-dose on Day 1, centre grouping, Day, Day by BL and Day by treatment interactions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Clinic Visit Trough (Pre-bronchodilator and Pre-dose) FEV1 at Day 169</measure>
    <time_frame>Baseline to Day 169</time_frame>
    <description>Co-Primary Endpoint: Pulmonary function was measured by forced expiratory volume in one second (FEV1), defined as the maximal amount of air that can be forcefully exhaled from the lungs in one second. Trough FEV1 measurements were taken electronically by spirometry on Days 2, 7, 14, 28, 56, 84, 112, 140, 168, and 169. BL was defined as the mean of the assessments made 30 minutes pre-dose and 5 minutes pre-dose on Treatment Day 1.Trough FEV1 was defined as the mean of the FEV1 values obtained 23 and 24 hours after previous morning's dosing. Change from BL was calculated as the average at each visit minus the BL value. Analysis was performed using a repeated measures model with covariates of treatment, smoking status at screening (stratum), BL - mean of the two assessments made 30 minutes pre-dose and immediately pre-dose on Day 1, centre grouping, Day, Day by BL and Day by treatment interactions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Chronic Respiratory Disease Questionnaire Self-administered Standardized (CRQ-SAS) Dyspnea Score at Day 168</measure>
    <time_frame>Baseline to Day 168</time_frame>
    <description>Considered an 'Other' endpoint by FDA. CRQ-SAS measures 4 domains (mastery, fatigue, emotional function, and dyspnea) of functioning of participants with COPD: mastery (amount of control the participant feels he/she has over COPD symptoms); fatigue (how tired the participant feels); emotional function (how anxious/depressed the participant feels); and dyspnea (how short of breath the participant feels during physical activities). Each domain is measured on a scale of 1-7 (1=maximum impairment; 7=no impairment). Each domain score is calculated separately. Current assessment was done only for dyspnea domain. BL scores are the derived scores for each domain and total at Day 1 pre-dose. Change from BL was calculated as the average at each visit minus the BL value. Analysis performed used a repeated measures model with covariates of treatment, smoking status at screening (stratum), BL (derived scores at Day 1 pre-dose), centre grouping, Day, Day by BL and Day by treatment interactions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Peak Post-dose FEV1 (0-4 Hour) on Day 1</measure>
    <time_frame>Baseline and Day 1</time_frame>
    <description>Pulmonary function was measured by forced expiratory volume in one second (FEV1), defined as the maximal amount of air that can be forcefully exhaled from the lungs in one second. BL FEV1 is defined as the mean of the assessments made 30 minutes pre-dose and immediately pre-dose on Day 1. If one of these two assessments was missing then BL was defined as the single pre-dose FEV1 value on Day 1. Peak post-dose FEV1 (0-4 hours) is the maximum post-dose FEV1 recorded over the nominal timepoints of 5, 15 and 30 min, 1, 2 and 4 hours post the Day 1 dose. Change from BL is calculated as the peak post-dose FEV1 (0-4 hour) on Day 1 minus BL FEV1. Analysis performed used an Analysis of Covariance (ANCOVA) model with covariates of treatment, smoking status at screening (stratum), BL - mean of the two assessments made 30 minutes pre-dose and immediately pre-dose on Day 1, and centre grouping.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset (Increase of 100 Milliliter [mL] From Baseline in 0-4 Hours Post-dose FEV1) on Treatment Day 1</measure>
    <time_frame>Baseline and Day 1</time_frame>
    <description>Pulmonary function was measured by forced expiratory volume in one second (FEV1), defined as the maximal amount of air that can be forcefully exhaled from the lungs in one second. Baseline FEV1 is defined as the mean of the two assessments made 30 minutes pre-dose and immediately pre-dose on Day 1. Time to onset on Treatment Day 1 is defined as a 100 mL increase from Baseline in FEV1. Time to increase of 100 mL from Baseline was calculated over the 5, 15, 30 minutes, and 1, 2, and 4 hours time points. A participant who had at least one post-dose FEV1 on Day 1, but did not achieve a 100 mL or more increase from Baseline at any scheduled time-point at which FEV1 was assessed up to and including 4 hours was censored.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1031</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>FF/GW642444 Inhalation Powder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FF Inhalation Powder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled Corticosteroid (ICS)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GW642444 Inhalation Powder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Long Acting Beta Agonist(LABA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FF/GW642444 Inhalation Pwdr</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FF/GW642444 Inhalation Powder</intervention_name>
    <description>Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD</description>
    <arm_group_label>FF/GW642444 Inhalation Powder</arm_group_label>
    <arm_group_label>FF/GW642444 Inhalation Pwdr</arm_group_label>
    <other_name>FF Inhalation Powder</other_name>
    <other_name>Placebo</other_name>
    <other_name>GW642444 Inhalation Powder</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FF Inhalation Powder</intervention_name>
    <description>Inhaled Corticosteroid (ICS)</description>
    <arm_group_label>FF Inhalation Powder</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW642444 Inhalation Powder</intervention_name>
    <description>Long Acting Beta Agonist(LABA)</description>
    <arm_group_label>GW642444 Inhalation Powder</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type of subject: outpatient

          -  Informed consent: Subjects must give their signed and dated written informed consent
             to participate.

          -  Gender: Male or female subjects A female is eligible to enter and participate in the
             study if she is of:

          -  Non-child bearing potential OR

          -  Child bearing potential, has a negative pregnancy test at screening, and agrees to one
             of the acceptable contraceptive methods defined in the protocol

          -  Age: ≥40 years of age at Screening (Visit 1)

          -  COPD diagnosis: Subjects with a clinical history of COPD in accordance with the
             definition by the American Thoracic Society/European Respiratory Society [Celli, 2004]

          -  Tobacco use: Subjects with a current or prior history of ≥10 pack-years of cigarette
             smoking at Screening (Visit 1).

          -  Severity of Disease: Subjects with a Screening (Visit 1) measured
             post-albuterol/salbutamol:

          -  FEV1/FVC ratio of ≤0.70 and

          -  FEV1 ≤70% of predicted normal values

          -  Dyspnea: Achieved a score of ≥2 on the Modified Medical Research Council Dyspnea Scale
             (mMRC) at Screening (Visit 1).

        Exclusion Criteria:

        Subjects meeting any of the following criteria must not be enrolled in the study:

          -  Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant
             during the study.

          -  Asthma: Subjects with a current diagnosis of asthma

          -  α1-antitrypsin deficiency: Subjects with α1-antitrypsin deficiency as the underlying
             cause of COPD

          -  Other respiratory disorders: Subjects with active tuberculosis, lung cancer,
             bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung
             diseases, or other active pulmonary diseases

          -  Lung resection: Subjects with lung volume reduction surgery within the 12 months prior
             to Screening (Visit 1)

          -  Chest X-ray (or CT scan): Subjects with a chest X-ray (or CT scan) that reveals
             evidence of clinically significant abnormalities not believed to be due to the
             presence of COPD.

          -  Hospitalization: Subjects who are hospitalized due to poorly controlled COPD within 12
             weeks of Visit 1.

          -  Poorly controlled COPD: Subjects with poorly controlled COPD, defined as the
             occurrence of the following in the 6 weeks prior to Visit 1: Acute worsening of COPD
             that is managed by subject with corticosteroids or antibiotics or that requires
             treatment prescribed by a physician.

          -  Lower respiratory tract infection: Subjects with lower respiratory tract infection
             that required the use of antibiotics within 6 weeks prior to Visit 1.

          -  Other diseases/abnormalities: Subjects with historical or current evidence of
             clinically significant cardiovascular (i.e., pacemaker), neurological, psychiatric,
             renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid
             disease) or haematological abnormalities that are uncontrolled.

          -  Peptic Ulcer disease: Subjects with clinically significant peptic ulcer disease that
             is uncontrolled.

          -  Hypertension: Subjects with clinically significant hypertension that is uncontrolled.

          -  Cancer: Subjects with carcinoma that has not been in complete remission for at least 5
             years. Carcinoma in situ of the cervix, squamous cell carcinoma and basal cell
             carcinoma of the skin would not be excluded if the subject has been considered cured
             within 5 years since diagnosis.

          -  Drug/food allergy: Subjects with a history of hypersensitivity to any of the study
             medication or components of the inhalation powder

          -  Drug/alcohol abuse: Subjects with a known or suspected history of alcohol or drug
             abuse within the last 2 years

          -  Medication prior to spirometry: Subjects who are medically unable to withhold their
             albuterol/salbutamol and/or their ipratropium 4 hours prior to spirometry testing at
             each study visit

          -  Additional medication: Use of certain medications such as bronchodilators and
             corticosteroids for the protocol-specified times prior to Visit 1 (the Investigator
             will discuss the specific medications)

          -  Oxygen therapy: Subjects receiving treatment with long-term oxygen therapy (LTOT) or
             nocturnal oxygen therapy required for greater than 12 hours a day. Oxygen prn use
             (i.e., ≤12 hours per day) is not exclusionary.

          -  Sleep apnea: Subjects with clinically significant sleep apnea who require use of
             continuous positive airway pressure (CPAP) device or non-invasive positive pressure
             ventilation (NIPPV) device.

          -  Pulmonary rehabilitation: Subjects who have participated in the acute phase of a
             Pulmonary Rehabilitation Program within 4 weeks prior to Screening (Visit 1) or who
             will enter the acute phase of a Pulmonary Rehabilitation Program during the study.

          -  Non-compliance: Subjects at risk of non-compliance, or unable to comply with the study
             procedures. Any infirmity, disability, or geographic location that would limit
             compliance for scheduled visits.

          -  Questionable validity of consent: Subjects with a history of psychiatric disease,
             intellectual deficiency, poor motivation or other conditions that will limit the
             validity of informed consent to participate in the study.

          -  Prior use of study medication/other investigational drugs

          -  Affiliation with investigator site: Study investigators, sub-investigators, study
             coordinators, employees of a participating investigator or immediate family members of
             the aforementioned are excluded from participating in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <zip>36106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sepulveda</city>
        <state>California</state>
        <zip>91343</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33755</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <zip>32405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Austell</city>
        <state>Georgia</state>
        <zip>30106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Coeur d'Alene</city>
        <state>Idaho</state>
        <zip>83814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hazard</city>
        <state>Kentucky</state>
        <zip>41701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madisonville</city>
        <state>Kentucky</state>
        <zip>42431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sunset</city>
        <state>Louisiana</state>
        <zip>70584</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Livonia</city>
        <state>Michigan</state>
        <zip>48152</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55438</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406-7108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gaffney</city>
        <state>South Carolina</state>
        <zip>29340</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pelzer</city>
        <state>South Carolina</state>
        <zip>29669</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wichita Falls</city>
        <state>Texas</state>
        <zip>76309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Puente Alto - Santiago</city>
        <state>Región Metro De Santiago</state>
        <zip>8207257</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago</city>
        <state>Región Metro De Santiago</state>
        <zip>7500691</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago</city>
        <state>Región Metro De Santiago</state>
        <zip>7601003</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valparaiso</city>
        <state>Valparaíso</state>
        <zip>2341131</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago</city>
        <zip>8380453</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Parnu</city>
        <zip>80010</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tallinn</city>
        <zip>10138</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tallinn</city>
        <zip>13619</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tartu</city>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Deggingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>73326</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Schwetzingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>68723</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aschaffenburg</city>
        <state>Bayern</state>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <zip>91052</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>80802</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>80809</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ruedersdorf</city>
        <state>Brandenburg</state>
        <zip>15562</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eschwege</city>
        <state>Hessen</state>
        <zip>37269</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kassel</city>
        <state>Hessen</state>
        <zip>34121</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ruesselsheim</city>
        <state>Hessen</state>
        <zip>65428</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dortmund</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44263</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gelsenkirchen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45879</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Magdeburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>39112</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Goerlitz</city>
        <state>Sachsen</state>
        <zip>02826</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Luebeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23552</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Schmoelln</city>
        <state>Thueringen</state>
        <zip>04626</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20253</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>815-8588</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>832-0059</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ibaraki</city>
        <zip>319-1113</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kagawa</city>
        <zip>762-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kanagawa</city>
        <zip>232-0066</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nagano</city>
        <zip>382-0091</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>596-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shizuoka</city>
        <zip>438-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>145-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>187-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucheon-si,</city>
        <zip>420-767</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Daegu</city>
        <zip>705-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>431-070</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Incheon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kangwon-do</city>
        <zip>220-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>130-848</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>143-729</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>152-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Uijeongbu-si, Kyonggi-do</city>
        <zip>480-130</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Monterrey NL</city>
        <state>Nuevo León</state>
        <zip>64718</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64060</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mexico City</city>
        <zip>07760</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Iloilo City</city>
        <zip>5000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lipa City</city>
        <zip>4217</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pasig City</city>
        <zip>1600</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1100</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1101</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-084</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-540</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80-405</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Grudziadz</city>
        <zip>86-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-023</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lodz</city>
        <zip>93-329</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lodz</city>
        <zip>93-504</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ostrow Wielkopolski</city>
        <zip>63-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wilkowice</city>
        <zip>43-365</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wodzislaw Slaski</city>
        <zip>44-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zabrze</city>
        <zip>41-800</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barnaul</city>
        <zip>656 045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620109</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Irkutsk</city>
        <zip>664005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>119620</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pyatigorsk</city>
        <zip>357538</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Samara</city>
        <zip>443079</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shakhty, Rostov region</city>
        <zip>346510</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tomsk</city>
        <zip>634001</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tumen</city>
        <zip>625023</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ufa</city>
        <zip>450071</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
    <country>Estonia</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Kerwin EM, Scott-Wilson C, Sanford L, Rennard S, Agusti A, Barnes N, Crim C. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD. Respir Med. 2013 Apr;107(4):560-9. doi: 10.1016/j.rmed.2012.12.014. Epub 2013 Jan 23. Erratum in: Respir Med. 2013 Dec;107(12):2094.</citation>
    <PMID>23352226</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2010</study_first_submitted>
  <study_first_submitted_qc>January 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2010</study_first_posted>
  <results_first_submitted>June 12, 2013</results_first_submitted>
  <results_first_submitted_qc>June 12, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 15, 2013</results_first_posted>
  <disposition_first_submitted>February 16, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>February 16, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 20, 2012</disposition_first_posted>
  <last_update_submitted>May 1, 2017</last_update_submitted>
  <last_update_submitted_qc>May 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>Efficacy</keyword>
  <keyword>FEV1</keyword>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>112206</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112206</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112206</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112206</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112206</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112206</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112206</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Eligible participants (par.) completed a 2-week single-blind (placebo) Run-in Period (RIP) to assess Baseline rescue use, symptoms, disease stability. Par. were then randomized to a 24-week Treatment Period. A total of 1804 par. were screened, 1390 entered the RIP, of whom 1031 were randomized, 1030 received at least one dose of study medication.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Run-in</title>
          <description>Participants received placebo once daily (OD) in the morning for 2 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants received placebo once daily (OD) in the morning from the dry powder inhaler (DPI) for 24 weeks.</description>
        </group>
        <group group_id="P3">
          <title>FF 100 µg OD</title>
          <description>Participants received Fluticasone Furoate (FF) 100 micrograms (µg) OD in the morning from the DPI for 24 weeks.</description>
        </group>
        <group group_id="P4">
          <title>VI 25 µg OD</title>
          <description>Participants received Vilanterol (VI [GW642444]) 25 µg OD in the morning from the DPI for 24 weeks.</description>
        </group>
        <group group_id="P5">
          <title>FF/VI 50/25 µg OD</title>
          <description>Participants received FF/VI 50/25 µg OD in the morning from the DPI for 24 weeks.</description>
        </group>
        <group group_id="P6">
          <title>FF/VI 100/25 µg OD</title>
          <description>Participants received FF/VI 100/25 µg OD in the morning from the DPI for 24 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>2-week, Single-blind Run-In Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1390"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1030"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="360"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did Not Meet Continuation Criteria</title>
              <participants_list>
                <participants group_id="P1" count="220"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Closed/Terminated</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>24-week, Double-blind Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="207"/>
                <participants group_id="P3" count="206"/>
                <participants group_id="P4" count="205"/>
                <participants group_id="P5" count="206"/>
                <participants group_id="P6" count="206"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="138"/>
                <participants group_id="P3" count="145"/>
                <participants group_id="P4" count="142"/>
                <participants group_id="P5" count="147"/>
                <participants group_id="P6" count="151"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="69"/>
                <participants group_id="P3" count="61"/>
                <participants group_id="P4" count="63"/>
                <participants group_id="P5" count="59"/>
                <participants group_id="P6" count="55"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="24"/>
                <participants group_id="P5" count="17"/>
                <participants group_id="P6" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy-No Sub-Reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy-Sub-Reason Exacerbation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Met Protocol-Defined Stopping Criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received placebo OD in the morning from the DPI for 24 weeks.</description>
        </group>
        <group group_id="B2">
          <title>FF 100 µg OD</title>
          <description>Participants received FF 100 µg OD in the morning from the DPI for 24 weeks.</description>
        </group>
        <group group_id="B3">
          <title>VI 25 µg OD</title>
          <description>Participants received VI 25 µg OD in the morning from the DPI for 24 weeks.</description>
        </group>
        <group group_id="B4">
          <title>FF/VI 50/25 µg OD</title>
          <description>Participants received FF/VI 50/25 µg OD in the morning from the DPI for 24 weeks.</description>
        </group>
        <group group_id="B5">
          <title>FF/VI 100/25 µg OD</title>
          <description>Participants received FF/VI 100/25 µg OD in the morning from the DPI for 24 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="207"/>
            <count group_id="B2" value="206"/>
            <count group_id="B3" value="205"/>
            <count group_id="B4" value="206"/>
            <count group_id="B5" value="206"/>
            <count group_id="B6" value="1030"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.1" spread="8.80"/>
                    <measurement group_id="B2" value="62.7" spread="9.47"/>
                    <measurement group_id="B3" value="63.4" spread="9.58"/>
                    <measurement group_id="B4" value="62.8" spread="9.13"/>
                    <measurement group_id="B5" value="62.3" spread="8.49"/>
                    <measurement group_id="B6" value="62.7" spread="9.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="71"/>
                    <measurement group_id="B5" value="69"/>
                    <measurement group_id="B6" value="345"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="141"/>
                    <measurement group_id="B2" value="132"/>
                    <measurement group_id="B3" value="140"/>
                    <measurement group_id="B4" value="135"/>
                    <measurement group_id="B5" value="137"/>
                    <measurement group_id="B6" value="685"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African American/African Heritage (HER)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Central/South Asian HER</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japanese/East Asian HER/South East Asian HER</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="46"/>
                    <measurement group_id="B6" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="155"/>
                    <measurement group_id="B2" value="139"/>
                    <measurement group_id="B3" value="141"/>
                    <measurement group_id="B4" value="156"/>
                    <measurement group_id="B5" value="150"/>
                    <measurement group_id="B6" value="741"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Weighted Mean FEV1 Over 0-4 Hours Post-dose at Day 168</title>
        <description>Co-Primary Endpoint: Pulmonary function was measured by forced expiratory volume in one second (FEV1), defined as the maximal amount of air that can be forcefully exhaled from the lungs in one second. Serial FEV1 measurements were taken electronically by spirometry at BL, weeks 2, 8, 12, and 84 (Day 168). Weighted mean (WM) was calculated using the 0 - 4 h post-dose FEV1 measurements that included the pre-dose (Day 1: 30 minutes [min] and 5 min prior to dosing; other serial visits:23 and 24 h after previous morning dose) and post-dose (5, 15, and 30 min and 1, 2, and 4 h) assessments. BL FEV1 is the mean of the two assessments made 30 and 5 min pre-dose at Day 1. WM change from BL was the WM at the visit minus the BL value. Analysis was performed using a repeated measures model with covariates of treatment, smoking status at screening (stratum), BL- mean of the two assessments made 30 and 5 min pre-dose on Day 1, centre grouping, Day, Day by BL and Day by treatment interactions.</description>
        <time_frame>Baseline (BL) to Day 168</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized par. who received at least one dose of study medication. Number of par. presented represent those with data available at the time point being presented; however, all par. in the ITT population without missing covariate information and with at least one post BL measurement are included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo OD in the morning from the DPI for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>FF 100 µg OD</title>
            <description>Participants received FF 100 µg OD in the morning from the DPI for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>VI 25 µg OD</title>
            <description>Participants received VI 25 µg OD in the morning from the DPI for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>FF/VI 50/25 µg OD</title>
            <description>Participants received FF/VI 50/25 µg OD in the morning from the DPI for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>FF/VI 100/25 µg OD</title>
            <description>Participants received FF/VI 100/25 µg OD in the morning from the DPI for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Weighted Mean FEV1 Over 0-4 Hours Post-dose at Day 168</title>
          <description>Co-Primary Endpoint: Pulmonary function was measured by forced expiratory volume in one second (FEV1), defined as the maximal amount of air that can be forcefully exhaled from the lungs in one second. Serial FEV1 measurements were taken electronically by spirometry at BL, weeks 2, 8, 12, and 84 (Day 168). Weighted mean (WM) was calculated using the 0 - 4 h post-dose FEV1 measurements that included the pre-dose (Day 1: 30 minutes [min] and 5 min prior to dosing; other serial visits:23 and 24 h after previous morning dose) and post-dose (5, 15, and 30 min and 1, 2, and 4 h) assessments. BL FEV1 is the mean of the two assessments made 30 and 5 min pre-dose at Day 1. WM change from BL was the WM at the visit minus the BL value. Analysis was performed using a repeated measures model with covariates of treatment, smoking status at screening (stratum), BL- mean of the two assessments made 30 and 5 min pre-dose on Day 1, centre grouping, Day, Day by BL and Day by treatment interactions.</description>
          <population>Intent-to-Treat (ITT) Population: all randomized par. who received at least one dose of study medication. Number of par. presented represent those with data available at the time point being presented; however, all par. in the ITT population without missing covariate information and with at least one post BL measurement are included in the analysis</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="144"/>
                <count group_id="O4" value="146"/>
                <count group_id="O5" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.026" spread="0.0184"/>
                    <measurement group_id="O2" value="0.080" spread="0.0182"/>
                    <measurement group_id="O3" value="0.129" spread="0.0182"/>
                    <measurement group_id="O4" value="0.218" spread="0.0181"/>
                    <measurement group_id="O5" value="0.200" spread="0.0179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.040</p_value>
            <p_value_desc>Nominal p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.053</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.003</ci_lower_limit>
            <ci_upper_limit>0.104</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.103</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.052</ci_lower_limit>
            <ci_upper_limit>0.153</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Nominal p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.192</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.141</ci_lower_limit>
            <ci_upper_limit>0.243</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.173</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.123</ci_lower_limit>
            <ci_upper_limit>0.224</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.120</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.070</ci_lower_limit>
            <ci_upper_limit>0.170</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Nominal p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.090</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.039</ci_lower_limit>
            <ci_upper_limit>0.140</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <p_value_desc>Nominal p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.071</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.021</ci_lower_limit>
            <ci_upper_limit>0.121</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Clinic Visit Trough (Pre-bronchodilator and Pre-dose) FEV1 at Day 169</title>
        <description>Co-Primary Endpoint: Pulmonary function was measured by forced expiratory volume in one second (FEV1), defined as the maximal amount of air that can be forcefully exhaled from the lungs in one second. Trough FEV1 measurements were taken electronically by spirometry on Days 2, 7, 14, 28, 56, 84, 112, 140, 168, and 169. BL was defined as the mean of the assessments made 30 minutes pre-dose and 5 minutes pre-dose on Treatment Day 1.Trough FEV1 was defined as the mean of the FEV1 values obtained 23 and 24 hours after previous morning's dosing. Change from BL was calculated as the average at each visit minus the BL value. Analysis was performed using a repeated measures model with covariates of treatment, smoking status at screening (stratum), BL - mean of the two assessments made 30 minutes pre-dose and immediately pre-dose on Day 1, centre grouping, Day, Day by BL and Day by treatment interactions.</description>
        <time_frame>Baseline to Day 169</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized par. who received at least one dose of study medication. Number of par. presented represent those with data available at the time point being presented; however, all par. in the ITT population without missing covariate information and with at least one post BL measurement are included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo OD in the morning from the DPI for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>FF 100 µg OD</title>
            <description>Participants received FF 100 µg OD in the morning from the DPI for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>VI 25 µg OD</title>
            <description>Participants received VI 25 µg OD in the morning from the DPI for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>FF/VI 50/25 µg OD</title>
            <description>Participants received FF/VI 50/25 µg OD in the morning from the DPI for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>FF/VI 100/25 µg OD</title>
            <description>Participants received FF/VI 100/25 µg OD in the morning from the DPI for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinic Visit Trough (Pre-bronchodilator and Pre-dose) FEV1 at Day 169</title>
          <description>Co-Primary Endpoint: Pulmonary function was measured by forced expiratory volume in one second (FEV1), defined as the maximal amount of air that can be forcefully exhaled from the lungs in one second. Trough FEV1 measurements were taken electronically by spirometry on Days 2, 7, 14, 28, 56, 84, 112, 140, 168, and 169. BL was defined as the mean of the assessments made 30 minutes pre-dose and 5 minutes pre-dose on Treatment Day 1.Trough FEV1 was defined as the mean of the FEV1 values obtained 23 and 24 hours after previous morning's dosing. Change from BL was calculated as the average at each visit minus the BL value. Analysis was performed using a repeated measures model with covariates of treatment, smoking status at screening (stratum), BL - mean of the two assessments made 30 minutes pre-dose and immediately pre-dose on Day 1, centre grouping, Day, Day by BL and Day by treatment interactions.</description>
          <population>Intent-to-Treat (ITT) Population: all randomized par. who received at least one dose of study medication. Number of par. presented represent those with data available at the time point being presented; however, all par. in the ITT population without missing covariate information and with at least one post BL measurement are included in the analysis</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="143"/>
                <count group_id="O4" value="144"/>
                <count group_id="O5" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.037" spread="0.0199"/>
                    <measurement group_id="O2" value="0.070" spread="0.0196"/>
                    <measurement group_id="O3" value="0.103" spread="0.0196"/>
                    <measurement group_id="O4" value="0.166" spread="0.0196"/>
                    <measurement group_id="O5" value="0.151" spread="0.0194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.241</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.033</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.022</ci_lower_limit>
            <ci_upper_limit>0.088</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.067</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.012</ci_lower_limit>
            <ci_upper_limit>0.121</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Nominal p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.129</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.074</ci_lower_limit>
            <ci_upper_limit>0.184</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.115</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.060</ci_lower_limit>
            <ci_upper_limit>0.169</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>Nominal p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.082</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.028</ci_lower_limit>
            <ci_upper_limit>0.136</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.025</p_value>
            <p_value_desc>Nominal p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.062</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.008</ci_lower_limit>
            <ci_upper_limit>0.117</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.082</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.048</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.006</ci_lower_limit>
            <ci_upper_limit>0.102</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Chronic Respiratory Disease Questionnaire Self-administered Standardized (CRQ-SAS) Dyspnea Score at Day 168</title>
        <description>Considered an ‘Other’ endpoint by FDA. CRQ-SAS measures 4 domains (mastery, fatigue, emotional function, and dyspnea) of functioning of participants with COPD: mastery (amount of control the participant feels he/she has over COPD symptoms); fatigue (how tired the participant feels); emotional function (how anxious/depressed the participant feels); and dyspnea (how short of breath the participant feels during physical activities). Each domain is measured on a scale of 1-7 (1=maximum impairment; 7=no impairment). Each domain score is calculated separately. Current assessment was done only for dyspnea domain. BL scores are the derived scores for each domain and total at Day 1 pre-dose. Change from BL was calculated as the average at each visit minus the BL value. Analysis performed used a repeated measures model with covariates of treatment, smoking status at screening (stratum), BL (derived scores at Day 1 pre-dose), centre grouping, Day, Day by BL and Day by treatment interactions.</description>
        <time_frame>Baseline to Day 168</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized par. who received at least one dose of study medication. Number of par. presented represent those with data available at the time point being presented; however, all par. in the ITT population without missing covariate information and with at least one post BL measurement are included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo OD in the morning from the DPI for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>FF 100 µg OD</title>
            <description>Participants received FF 100 µg OD in the morning from the DPI for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>VI 25 µg OD</title>
            <description>Participants received VI 25 µg OD in the morning from the DPI for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>FF/VI 50/25 µg OD</title>
            <description>Participants received FF/VI 50/25 µg OD in the morning from the DPI for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>FF/VI 100/25 µg OD</title>
            <description>Participants received FF/VI 100/25 µg OD in the morning from the DPI for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chronic Respiratory Disease Questionnaire Self-administered Standardized (CRQ-SAS) Dyspnea Score at Day 168</title>
          <description>Considered an ‘Other’ endpoint by FDA. CRQ-SAS measures 4 domains (mastery, fatigue, emotional function, and dyspnea) of functioning of participants with COPD: mastery (amount of control the participant feels he/she has over COPD symptoms); fatigue (how tired the participant feels); emotional function (how anxious/depressed the participant feels); and dyspnea (how short of breath the participant feels during physical activities). Each domain is measured on a scale of 1-7 (1=maximum impairment; 7=no impairment). Each domain score is calculated separately. Current assessment was done only for dyspnea domain. BL scores are the derived scores for each domain and total at Day 1 pre-dose. Change from BL was calculated as the average at each visit minus the BL value. Analysis performed used a repeated measures model with covariates of treatment, smoking status at screening (stratum), BL (derived scores at Day 1 pre-dose), centre grouping, Day, Day by BL and Day by treatment interactions.</description>
          <population>Intent-to-Treat (ITT) Population: all randomized par. who received at least one dose of study medication. Number of par. presented represent those with data available at the time point being presented; however, all par. in the ITT population without missing covariate information and with at least one post BL measurement are included in the analysis</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="140"/>
                <count group_id="O4" value="145"/>
                <count group_id="O5" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.088"/>
                    <measurement group_id="O2" value="0.29" spread="0.086"/>
                    <measurement group_id="O3" value="0.37" spread="0.086"/>
                    <measurement group_id="O4" value="0.42" spread="0.085"/>
                    <measurement group_id="O5" value="0.53" spread="0.085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Peak Post-dose FEV1 (0-4 Hour) on Day 1</title>
        <description>Pulmonary function was measured by forced expiratory volume in one second (FEV1), defined as the maximal amount of air that can be forcefully exhaled from the lungs in one second. BL FEV1 is defined as the mean of the assessments made 30 minutes pre-dose and immediately pre-dose on Day 1. If one of these two assessments was missing then BL was defined as the single pre-dose FEV1 value on Day 1. Peak post-dose FEV1 (0-4 hours) is the maximum post-dose FEV1 recorded over the nominal timepoints of 5, 15 and 30 min, 1, 2 and 4 hours post the Day 1 dose. Change from BL is calculated as the peak post-dose FEV1 (0-4 hour) on Day 1 minus BL FEV1. Analysis performed used an Analysis of Covariance (ANCOVA) model with covariates of treatment, smoking status at screening (stratum), BL - mean of the two assessments made 30 minutes pre-dose and immediately pre-dose on Day 1, and centre grouping.</description>
        <time_frame>Baseline and Day 1</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants who received at least one dose of study medication. Only those participants available at the indicated time point and without missing covariate information were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo OD in the morning from the DPI for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>FF 100 µg OD</title>
            <description>Participants received FF 100 µg OD in the morning from the DPI for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>VI 25 µg OD</title>
            <description>Participants received VI 25 µg OD in the morning from the DPI for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>FF/VI 50/25 µg OD</title>
            <description>Participants received FF/VI 50/25 µg OD in the morning from the DPI for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>FF/VI 100/25 µg OD</title>
            <description>Participants received FF/VI 100/25 µg OD in the morning from the DPI for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Peak Post-dose FEV1 (0-4 Hour) on Day 1</title>
          <description>Pulmonary function was measured by forced expiratory volume in one second (FEV1), defined as the maximal amount of air that can be forcefully exhaled from the lungs in one second. BL FEV1 is defined as the mean of the assessments made 30 minutes pre-dose and immediately pre-dose on Day 1. If one of these two assessments was missing then BL was defined as the single pre-dose FEV1 value on Day 1. Peak post-dose FEV1 (0-4 hours) is the maximum post-dose FEV1 recorded over the nominal timepoints of 5, 15 and 30 min, 1, 2 and 4 hours post the Day 1 dose. Change from BL is calculated as the peak post-dose FEV1 (0-4 hour) on Day 1 minus BL FEV1. Analysis performed used an Analysis of Covariance (ANCOVA) model with covariates of treatment, smoking status at screening (stratum), BL - mean of the two assessments made 30 minutes pre-dose and immediately pre-dose on Day 1, and centre grouping.</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants who received at least one dose of study medication. Only those participants available at the indicated time point and without missing covariate information were analyzed.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="206"/>
                <count group_id="O3" value="205"/>
                <count group_id="O4" value="205"/>
                <count group_id="O5" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.106" spread="0.0098"/>
                    <measurement group_id="O2" value="0.118" spread="0.0099"/>
                    <measurement group_id="O3" value="0.247" spread="0.0099"/>
                    <measurement group_id="O4" value="0.253" spread="0.0099"/>
                    <measurement group_id="O5" value="0.245" spread="0.0099"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset (Increase of 100 Milliliter [mL] From Baseline in 0-4 Hours Post-dose FEV1) on Treatment Day 1</title>
        <description>Pulmonary function was measured by forced expiratory volume in one second (FEV1), defined as the maximal amount of air that can be forcefully exhaled from the lungs in one second. Baseline FEV1 is defined as the mean of the two assessments made 30 minutes pre-dose and immediately pre-dose on Day 1. Time to onset on Treatment Day 1 is defined as a 100 mL increase from Baseline in FEV1. Time to increase of 100 mL from Baseline was calculated over the 5, 15, 30 minutes, and 1, 2, and 4 hours time points. A participant who had at least one post-dose FEV1 on Day 1, but did not achieve a 100 mL or more increase from Baseline at any scheduled time-point at which FEV1 was assessed up to and including 4 hours was censored.</description>
        <time_frame>Baseline and Day 1</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants who received at least one dose of study medication. Only those participants available at the indicated time point were assessed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo OD in the morning from the DPI for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>FF 100 µg OD</title>
            <description>Participants received FF 100 µg OD in the morning from the DPI for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>VI 25 µg OD</title>
            <description>Participants received VI 25 µg OD in the morning from the DPI for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>FF/VI 50/25 µg OD</title>
            <description>Participants received FF/VI 50/25 µg OD in the morning from the DPI for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>FF/VI 100/25 µg OD</title>
            <description>Participants received FF/VI 100/25 µg OD in the morning from the DPI for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset (Increase of 100 Milliliter [mL] From Baseline in 0-4 Hours Post-dose FEV1) on Treatment Day 1</title>
          <description>Pulmonary function was measured by forced expiratory volume in one second (FEV1), defined as the maximal amount of air that can be forcefully exhaled from the lungs in one second. Baseline FEV1 is defined as the mean of the two assessments made 30 minutes pre-dose and immediately pre-dose on Day 1. Time to onset on Treatment Day 1 is defined as a 100 mL increase from Baseline in FEV1. Time to increase of 100 mL from Baseline was calculated over the 5, 15, 30 minutes, and 1, 2, and 4 hours time points. A participant who had at least one post-dose FEV1 on Day 1, but did not achieve a 100 mL or more increase from Baseline at any scheduled time-point at which FEV1 was assessed up to and including 4 hours was censored.</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants who received at least one dose of study medication. Only those participants available at the indicated time point were assessed.</population>
          <units>Minutes</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="206"/>
                <count group_id="O3" value="205"/>
                <count group_id="O4" value="205"/>
                <count group_id="O5" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="5" upper_limit="240">&gt; 50% of participants were censored; therefore, the median could not be calculated.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="5" upper_limit="240">&gt; 50% of participants were censored; therefore, the median could not be calculated.</measurement>
                    <measurement group_id="O3" value="16" lower_limit="5" upper_limit="240"/>
                    <measurement group_id="O4" value="17" lower_limit="5" upper_limit="240"/>
                    <measurement group_id="O5" value="17" lower_limit="5" upper_limit="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of the study medication through the end of treatment (up to Week 24).</time_frame>
      <desc>An on-treatment AE or SAE is defined as an AE with an onset on or after the start date of study medication, but not later than one day after the last date of study medication. SAEs and AEs were collected in members of the ITT Population, comprised of all participants randomized to treatment, who received at least one dose of the study medication</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received placebo OD in the morning from the DPI for 24 weeks.</description>
        </group>
        <group group_id="E2">
          <title>FF 100 µg OD</title>
          <description>Participants received FF 100 µg OD in the morning from the DPI for 24 weeks.</description>
        </group>
        <group group_id="E3">
          <title>VI 25 µg OD</title>
          <description>Participants received VI 25 µg OD in the morning from the DPI for 24 weeks.</description>
        </group>
        <group group_id="E4">
          <title>FF/VI 50/25 µg OD</title>
          <description>Participants received FF/VI 50/25 µg OD in the morning from the DPI for 24 weeks.</description>
        </group>
        <group group_id="E5">
          <title>FF/VI 100/25 µg OD</title>
          <description>Participants received FF/VI 100/25 µg OD in the morning from the DPI for 24 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness neurosensory</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Fractured coccyx</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Transplant failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Glottis carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Lip and/or oral cavity cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Nasopharyngeal cancer stage IV</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Hypertonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Myasthenia gravis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="63" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Oropharyngeal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

